RxDoctor Payments Data

Ivo Drazenovic Navarro, MD

Family Medicine · Fort Myers, FLNPI 1497909345

Payments from drug & device makers

$4,098in general payments, 2019–2025

Across 129 payments — averaging $31.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$572
  • Lilly USA, LLC$376
  • Amarin Pharma, Inc.$283
  • Covidien LP$221
  • Boehringer Ingelheim$207
  • plus $644 from 9 others

What the payments were for

  • Food & beverage$4,098100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,098 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$36,588
Medicare patients
182
Services billed
315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$26,103
JardianceEmpagliflozin15$18,326
Atorvastatin Calcium65$834
Albuterol Sulfate HfaAlbuterol Sulfate20$570
Rosuvastatin Calcium36$566
Metoprolol Succinate30$354
Gabapentin21$343
Levothyroxine Sodium41$318
Ipratropium Bromide14$269
Fluticasone Propionate17$238
Losartan Potassium28$227
Pantoprazole Sodium17$195
Torsemide11$195
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide19$193
Amlodipine Besylate23$187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,795$26,10330 claims
Boehringer IngelheimJardiance$207$18,32615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →